Oncotelic Therapeutics Reports Q2 2026 Financial Results with Increased Revenue and Net Loss

Oncotelic Therapeutics, Inc. reported its financial results for the second quarter and first half of 2026, revealing a service revenue of $250,000, a significant increase from zero revenue in the same period of 2025. The company recorded a net income of approximately $388,000 for the three months ended June 30, 2026, compared to a net income of $278,000 for the same period in 2025. However, for the six months ended June 30, 2026, Oncotelic experienced a net loss of approximately $1.9 million, a substantial increase from a loss of $154,000 in the prior year. The increase in losses was attributed to higher operating expenses, particularly in general and administrative costs, which rose to $2.9 million from $166,000 in the previous year.

The company's total operating expenses for the second quarter of 2026 were approximately $1.1 million, up from $66,000 in the same quarter of 2025. This increase was primarily driven by a rise in general and administrative expenses, which included higher stock-based compensation and legal fees associated with efforts to uplist the company's stock to a national exchange. The company also reported a gain of $1.1 million from the derecognition of a non-financial asset related to its investment in Lunai Bioworks, alongside a $300,000 increase in the fair value of its equity investment in Lunai.

Oncotelic's balance sheet as of June 30, 2026, showed total assets of approximately $394.8 million, slightly up from $393.1 million at the end of 2025. The company maintained a cash position of $206,000, with total stockholders' equity increasing to $264.6 million from $262.8 million at the end of the previous year. The company’s liabilities remained stable, with total liabilities reported at approximately $131.3 million, reflecting a slight decrease from $131.4 million at the end of 2025.

Strategically, Oncotelic has made significant advancements through its joint venture with GMP Bio, focusing on the development of OT-101 for various oncology indications. The joint venture has initiated Phase 2 and Phase 3 clinical trials and is also developing a nanoparticle platform for drug delivery. Additionally, Oncotelic entered into a merger agreement with Lunai Bioworks, which included the transfer of intellectual property assets and the issuance of preferred stock valued at $12.5 million. The company is also exploring the commercialization of its PDAOAI-enabled robotics platform in partnership with TechForce Robotics.

Looking ahead, Oncotelic's management expressed the need to raise additional capital to support ongoing operations and product development. The company plans to continue its focus on advancing its pipeline, including OT-101 and other therapeutic candidates, while also evaluating opportunities for equity and debt financing. However, the company acknowledged that its ability to continue as a going concern is contingent upon securing sufficient funding, given its history of net losses and current working capital deficit.